Sai Parenterals: revenue ₹196 Cr, net profit ₹11 Cr
Results · Finvezto · 1 Nov 2026 · Sai Parenterals (SAIPARENT)
Results ₹ Cr
| Latest quarter | ₹ Cr | QoQ | YoY |
|---|---|---|---|
| Revenue | 196 | - | - |
| Operating profit | 41 | - | - |
| Net profit | 11 | - | - |
| Operating margin | 21.1% | - | - |
| Net margin | 5.4% | - | - |
YoY is the company's own figure. QoQ shows where our quarterly series matches the filing.
Key points
- Sai Parenterals Limited reported consolidated revenue from operations of Rs 196.1 crore for the quarter ended September 30, 2026, compared to Rs 54.9 crore in the year-ago quarter, with EBITDA rising to Rs 41.4 crore from Rs 12.8 crore and PAT increasing to Rs 10.5 crore from Rs 7.2 crore. NSE filing
- The company noted that year-on-year comparisons are not like-for-like due to the consolidation of Noumed Pharmaceuticals, and it completed the acquisitions of 60% stakes in Saicriti Pharma and Prathyak Laboratories. NSE filing
- Revenue was ₹196 Cr. Finvezto data
Links
NSE filing (PDF) · Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.